DPP-4 / SGLT2 (combination)

Class

Fixed-dose combination (DPP-4 inhibitor + SGLT2 inhibitor)

This combination pairs two oral agents that lower blood glucose in type 2 diabetes through distinct, complementary mechanisms. DPP-4 (dipeptidyl peptidase-4) is an enzyme that rapidly degrades incretin hormones, chiefly GLP-1 and GIP, which are released from the gut after meals and stimulate glucose-dependent insulin secretion while suppressing glucagon. Inhibiting DPP-4 prolongs incretin activity, improving glucose control mainly around meals with low intrinsic risk of hypoglycemia because its action depends on ambient glucose levels. SGLT2 (sodium-glucose cotransporter 2) is a transporter in the kidney's proximal tubule responsible for reabsorbing most filtered glucose back into the bloodstream. Blocking it causes excess glucose to be excreted in urine, lowering blood glucose independent of insulin signaling, and producing modest reductions in weight and blood pressure through associated calorie and fluid loss. Combining these mechanisms addresses glucose control from two directions - one enhancing the body's own insulin response, the other bypassing insulin biology entirely - which can improve overall glycemic control while allowing lower doses of each component. Fixed-dose combinations of this type are broadly relevant across the type 2 diabetes treatment landscape, particularly for patients who fail to reach glycemic targets on single agents.